



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/510,625
Applicant : Nava ZISAPEL
Filed : April 20, 2005
TC/A.U. : 1618
Examiner : Blessing M. Fubara

Docket No. : 2007-120
Customer No. : 06449
Confirmation No. : 9296

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98,
Applicant submits herewith information that the Office may wish
to consider in examination of the subject application. Materials
submitted for consideration are listed on the attached form PTO-
1449.

Respectfully submitted,

By Barbara G. Ernst
Barbara G. Ernst
Attorney for Applicants
Registration No. 30,377
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 783-6040

INFORMATION DISCLOSURE STATEMENT BY APPLICANT



INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/510,625
				Filing Date	April 20, 2005
				First Named Inventor	Nava ZISAPEL
				Group Art Unit	1618
				Examiner Name	Blessing M. Fubara
				Confirmation No.	9296
Sheet	1	of	3	Attorney Docket Number	2007-120

U.S. PATENT DOCUMENTS

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/510,625
				Filing Date	April 20, 2005
				First Named Inventor	Nava ZISAPEL
				Group Art Unit	1618
				Examiner Name	Blessing M. Fubara
				Confirmation No.	9296
Sheet	2	of	3	Attorney Docket Number	2007-120

FOREIGN PATENT DOCUMENTS

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind

of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/510,625
				Filing Date	April 20, 2005
				First Named Inventor	Nava ZISAPEL
				Group Art Unit	1618
				Examiner Name	Blessing M. Fubara
				Confirmation No.	9296
Sheet		3	of	3	Attorney Docket Number
2007-120					

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	AE	KIRKWOOD, Cynthia K., "Management of Insomnia," <i>Journal of the American Pharmaceutical Association</i> , September/October 1999, pp. 688-696, vol. 39, no. 5.			
	AF	NEUBAUER, David N., "Indiplon: the development of a new hypnotic," <i>Summary Expert Opinion on Investigational Drugs</i> , October 2005, pp. 1269-1276, vol. 14, no. 10. Abstract.			
	AG	NORMAN, Trevor R., et al., "The Effect of Single Oral Doses of Zopiclone on Nocturnal Melatonin Secretion in Healthy Male Volunteers," <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2001, pp. 825-833, vol. 25.			
	AH	REITER, Russel J., et al., "Reactive Oxygen Intermediates, Molecular Damage, and Aging," <i>Ann. NY Acad. Sci.</i> , Nov. 20, 1998, pp. 410-24, vol. 854.			
	AI	SUHNER, Andrea, et al., "Effectiveness and Tolerability of Melatonin and Zolpidem for the Alleviation of Jet Lag," <i>Aviation, Space and Environmental Medicine</i> , July 2001, pp. 638-646, vol. 72, no. 7.			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.